| Drug design strategies to avoid resistance in direct-acting antivirals and beyond AN Matthew, F Leidner, GJ Lockbaum, M Henes, J Zephyr, S Hou, ... Chemical reviews 121 (6), 3238-3270, 2021 | 45 | 2021 |
| Picomolar to micromolar: elucidating the role of distal mutations in HIV-1 protease in conferring drug resistance M Henes, GJ Lockbaum, K Kosovrasti, F Leidner, GS Nachum, ... ACS chemical biology 14 (11), 2441-2452, 2019 | 41 | 2019 |
| Structural adaptation of darunavir analogues against primary mutations in HIV-1 protease GJ Lockbaum, F Leidner, LN Rusere, M Henes, K Kosovrasti, GS Nachum, ... ACS infectious diseases 5 (2), 316-325, 2018 | 32 | 2018 |
| Pan-3C protease inhibitor rupintrivir binds SARS-CoV-2 main protease in a unique binding mode GJ Lockbaum, M Henes, JM Lee, J Timm, EA Nalivaika, PR Thompson, ... Biochemistry 60 (39), 2925-2931, 2021 | 24 | 2021 |
| HIV-1 protease inhibitors incorporating stereochemically defined P2′ ligands to optimize hydrogen bonding in the substrate envelope LN Rusere, GJ Lockbaum, SK Lee, M Henes, K Kosovrasti, E Spielvogel, ... Journal of medicinal chemistry 62 (17), 8062-8079, 2019 | 24 | 2019 |
| Molecular determinants of epistasis in HIV-1 protease: Elucidating the interdependence of L89V and L90M mutations in resistance M Henes, K Kosovrasti, GJ Lockbaum, F Leidner, GS Nachum, ... Biochemistry 58 (35), 3711-3726, 2019 | 20 | 2019 |
| Avoiding drug resistance by substrate envelope-guided design: toward potent and robust HCV NS3/4A protease inhibitors AN Matthew, J Zephyr, D Nageswara Rao, M Henes, W Kamran, ... MBio 11 (2), 10.1128/mbio. 00172-20, 2020 | 16 | 2020 |
| Inhibiting HTLV-1 protease: a viable antiviral target GJ Lockbaum, M Henes, N Talledge, LN Rusere, K Kosovrasti, ... ACS chemical biology 16 (3), 529-538, 2021 | 15 | 2021 |
| Selection of HIV-1 for resistance to fifth-generation protease inhibitors reveals two independent pathways to high-level resistance E Spielvogel, SK Lee, S Zhou, GJ Lockbaum, M Henes, A Sondgeroth, ... Elife 12, e80328, 2023 | 14 | 2023 |
| Discovery of quinoxaline-based p1–p3 macrocyclic ns3/4a protease inhibitors with potent activity against drug-resistant hepatitis C virus variants D Nageswara Rao, J Zephyr, M Henes, ET Chan, AN Matthew, ... Journal of medicinal chemistry 64 (16), 11972-11989, 2021 | 11 | 2021 |
| Molecular and structural mechanism of pan-genotypic HCV NS3/4A protease inhibition by glecaprevir J Timm, K Kosovrasti, M Henes, F Leidner, S Hou, A Ali, N Kurt Yilmaz, ... ACS chemical biology 15 (2), 342-352, 2019 | 9 | 2019 |
| Deciphering the molecular mechanism of HCV protease inhibitor Fluorination as a general approach to avoid drug resistance J Zephyr, DN Rao, SV Vo, M Henes, K Kosovrasti, AN Matthew, ... Journal of molecular biology 434 (9), 167503, 2022 | 6 | 2022 |
| Structural analysis of potent hybrid HIV-1 protease inhibitors containing Bis-tetrahydrofuran in a Pseudosymmetric dipeptide Isostere LN Rusere, GJ Lockbaum, M Henes, SK Lee, E Spielvogel, DN Rao, ... Journal of medicinal chemistry 63 (15), 8296-8313, 2020 | 5 | 2020 |
| Avoiding drug resistance by substrate envelope-guided design: toward potent and robust HCV NS3/4A protease inhibitors. mBio 11 (2): e00172-20 AN Matthew, J Zephyr, D Nageswara Rao, M Henes, W Kamran, ... | 5 | 2020 |
| HIV-1 protease inhibitors with a P1 phosphonate modification maintain potency against drug-resistant variants by increased interactions with flap residues GJ Lockbaum, LN Rusere, M Henes, K Kosovrasti, DN Rao, E Spielvogel, ... European Journal of Medicinal Chemistry 257, 115501, 2023 | 4 | 2023 |
| Foul ball rates and injuries at Major League Baseball games: a retrospective analysis of data from three stadiums A Milsten, WF Bradley, M Hill, W Sacco, M Henes Prehospital and Disaster Medicine 37 (2), 277-283, 2022 | 3 | 2022 |
| Correction to Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease GJ Lockbaum, F Leidner, LN Rusere, M Henes, K Kosovrasti, GS Nachum, ... ACS infectious diseases 5 (6), 1044-1044, 2019 | 1 | 2019 |
| Structural adaptation of Darunavir analogs against primary resistance mutations in HIV-1 protease GJ Lockbaum, F Leidner, LN Rusere, M Henes, K Kosovrasti, ... BioRxiv, 406637, 2018 | 1 | 2018 |
| Differential roles of putative arginine fingers of AAA+ ATPases Rvb1 and Rvb2 JL Warnock, JA Ball, SM Najmi, M Henes, A Vazquez, S Koshnevis, ... bioRxiv, 2024 | | 2024 |
| Antiviral Compounds CA SCHIFFER, A Ali, N Kurt-Yilmaz, LN Rusere, GJ Lockbaum, M Henes US Patent App. 18/074,219, 2023 | | 2023 |
Celia A SchifferProfessor and Chair of Biochemistry and Molecular Biotechnology, U Mass Chan Medical School在 umassmed.edu 的电子邮件经过验证
